Caris Life Sciences president granted 83,162 shares

Spetzler David Baxley reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/10/2026 - 05:59 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Spetzler David Baxley reported acquisition or exercise transactions in this Form 4 filing.

Caris Life Sciences, Inc. President David Baxley Spetzler received an award of 83,162 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and will vest in accordance with the applicable grant agreement. Following this compensation-related grant, he holds 543,939 shares of Common Stock directly.

Insider Trade Summary

Grant/Award: 83,162 shares

Grant/Award 1 txn

Insider Spetzler David Baxley

Role President

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	83,162	$0.00	$0.00

Holdings After Transaction: Common Stock — 543,939 shares (Direct)

Footnotes (1)

1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Caris Life Sciences (CAI) report for David Baxley Spetzler?

Caris Life Sciences reported that President David Baxley Spetzler received 83,162 shares of Common Stock as a restricted stock unit award. This is a compensation grant, not an open-market purchase, and increases his directly held position to 543,939 shares.

Was the Caris Life Sciences (CAI) insider transaction a stock purchase or a grant?

The transaction was a grant of restricted stock units, not an open-market purchase. Spetzler received 83,162 shares at a price of $0.00 per share as an equity award that will vest under the terms of a grant agreement.

How many Caris Life Sciences (CAI) shares does David Baxley Spetzler hold after this Form 4?

After the reported award, David Baxley Spetzler directly holds 543,939 shares of Caris Life Sciences Common Stock. This total reflects the addition of 83,162 restricted stock units granted as compensation, which vest according to an applicable grant agreement.

What type of security was involved in the latest Caris Life Sciences (CAI) insider filing?

The filing involves Common Stock delivered through a restricted stock unit award. Spetzler was granted 83,162 restricted stock units that convert into Common Stock as they vest, with no cash exercise price disclosed for the award.

Does the Caris Life Sciences (CAI) Form 4 indicate any insider share sales?

The Form 4 shows no insider sales. It reports only an acquisition through a restricted stock unit grant of 83,162 shares to President David Baxley Spetzler, increasing his direct holdings to 543,939 shares without any corresponding dispositions.

How do the restricted stock units for Caris Life Sciences (CAI) vest for David Baxley Spetzler?

The restricted stock units vest in accordance with the applicable grant agreement. The filing notes that the 83,162-share award is subject to vesting terms defined in that agreement, which will determine when the units convert into fully vested Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Spetzler David Baxley

(Last) (First) (Middle)

C/O CARIS LIFE SCIENCES, INC.

750 W. JOHN CARPENTER FREEWAY, SUITE 800

(Street)

IRVING TX 75039

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		A		83,162(1)	A	$0	543,939	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.

Remarks:

	/s/ J. Russel Denton, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.